Sentinel Lymph Node Dissection
- First applied to breast cancer patients in 1991
- first widespread use was for cutaneous melanoma
- SLN decreases axillary morbidity. Lymphedema is 1%-3%. Decreased risk of parethesias.
- The axillary recurrence rate was 0% with the negative sentinel lymph node group in one of the studies.
- Frozen section examinations of the lymph nodes in the OR has a false negative rate of 10-15%.
Axillary Lymph Node status in Breast Cancer
- Axillary lymph node status is the strongest prognostic indicator for breast cancer patients.
- Axillary lymph node status most likely doesn’t need identification with DCIS (Ductal Carcinoma In Situ) disease. There is less than a 1% chance of a positive lymph node status in the axilla with DCIS.
- If there is a suspicion of an invasive component of breast cancer than consider sentinel lymph node procedure for diagnosing Axillary lymph node status.